- Home
- LKFN vs BCYC Comparison
LKFN vs BCYC Comparison
Compare LKFN & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LKFN
- BCYC
- Stock Information
- Founded
- LKFN 1872
- BCYC 2009
- Country
- LKFN United States
- BCYC United Kingdom
- Employees
- LKFN N/A
- BCYC N/A
- Industry
- LKFN Major Banks
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- LKFN Finance
- BCYC Health Care
- Exchange
- LKFN Nasdaq
- BCYC Nasdaq
- Market Cap
- LKFN 1.7B
- BCYC 1.6B
- IPO Year
- LKFN 1997
- BCYC 2019
- Fundamental
- Price
- LKFN $63.47
- BCYC $23.60
- Analyst Decision
- LKFN Hold
- BCYC Buy
- Analyst Count
- LKFN 3
- BCYC 9
- Target Price
- LKFN $71.00
- BCYC $42.00
- AVG Volume (30 Days)
- LKFN 97.7K
- BCYC 478.9K
- Earning Date
- LKFN 10-23-2024
- BCYC 10-31-2024
- Dividend Yield
- LKFN 3.03%
- BCYC N/A
- EPS Growth
- LKFN 7.96
- BCYC N/A
- EPS
- LKFN 3.92
- BCYC N/A
- Revenue
- LKFN $243,098,000.00
- BCYC $39,574,000.00
- Revenue This Year
- LKFN N/A
- BCYC $58.69
- Revenue Next Year
- LKFN $1.19
- BCYC N/A
- P/E Ratio
- LKFN $15.92
- BCYC N/A
- Revenue Growth
- LKFN 2.24
- BCYC 75.74
- 52 Week Low
- LKFN $46.26
- BCYC $12.54
- 52 Week High
- LKFN $73.22
- BCYC $28.20
- Technical
- Relative Strength Index (RSI)
- LKFN 44.26
- BCYC 50.63
- Support Level
- LKFN $61.50
- BCYC $21.75
- Resistance Level
- LKFN $65.65
- BCYC $24.67
- Average True Range (ATR)
- LKFN 1.75
- BCYC 1.28
- MACD
- LKFN -0.43
- BCYC -0.23
- Stochastic Oscillator
- LKFN 20.63
- BCYC 39.96
About LKFN Lakeland Financial Corporation
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. Lakeland offers a broad range of products and services throughout its Northern and Central Indiana markets. The company offers commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.